Update on Russia Trials
Applied Clinical Trials
A recently released report details the current status of the clinical trials market in Russia.
A recently released report details the current status of the clinical trials market in Russia. According to the Russian CRO Synergy Research Group, the Federal Service on Surveillance in Healthcare and Social Development of the Russian Federation (alias RosZdravNadzor, RZN) approved 130 new clinical trials in Russia in first quarter 2008; that's four trials less than in the corresponding period last year.
The report noted that the main contribution is still made by multinational, multicenter clinical trials. The share of foreign study sponsors in first quarter 2008 stood at 68% of the total number of clinical trials, and 88 new trials were initiated during this period. To read the report from Synergy Research Group, go to www.synrgpharm.com/images/SynRG_Orange_Paper_2008Q1_E.pdf.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
